Analyzing Mereo BioPharma Group (NASDAQ:MREO) and Crescent Biopharma (NASDAQ:CBIO)

Crescent Biopharma (NASDAQ:CBIO) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Crescent Biopharma and Mereo BioPharma Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

Valuation & Earnings

This table compares Crescent Biopharma and Mereo BioPharma Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$11.88 million	59.23	-$153.94 million	($6.72)	-2.82
Mereo BioPharma Group	$500,000.00	87.83	-$41.88 million	($0.04)	-6.88

Mereo BioPharma Group has lower revenue, but higher earnings than Crescent Biopharma. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Crescent Biopharma has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Crescent Biopharma and Mereo BioPharma Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1	1	2	2	2.83
Mereo BioPharma Group	2	3	3	0	2.12

Crescent Biopharma presently has a consensus price target of $29.60, suggesting a potential upside of 56.20%. Mereo BioPharma Group has a consensus price target of $1.67, suggesting a potential upside of 506.06%. Given Mereo BioPharma Group’s higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Crescent Biopharma.

Insider & Institutional Ownership

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.